Literature DB >> 16954212

Rat spongiotrophoblast-specific protein is predominantly a unique low sulfated chondroitin sulfate proteoglycan.

Rajeshwara N Achur1, Sean T Agbor-Enoh, D Channe Gowda.   

Abstract

We have previously demonstrated that the human placenta contains a uniquely low sulfated extracellular aggrecan family chondroitin sulfate proteoglycan (CSPG). This CSPG is a major receptor for the adherence of Plasmodium falciparum-infected red blood cells (IRBCs) in placentas, causing pregnancy-specific malaria. However, it is not known whether such low sulfated CSPGs occur in placentas of other animals and, if so, whether IRBCs bind to those CSPGs. In this study, we show that rat placenta contains a uniquely low sulfated extracellular CSPG bearing chondroitin sulfate (CS) chains, which comprise only approximately 2% 4-sulfated and the remainder nonsulfated disaccharides. Surprisingly, the core protein of the rat placental CSPG, unlike that of the human placental CSPG, is a spongiotrophoblast-specific protein (SSP), which is expressed in a pregnancy stage-dependent manner. The majority of rat placental SSP is present in the CSPG form, and only approximately 10% occurs without CS chain substitution. Of the total SSP-CSPG in rat placenta, approximately 57% is modified with a single CS chain, and approximately 43% carries two CS chains. These data together with the previous finding on human placental CSPG suggest that the expression of low sulfated CSPG is a common feature of animal placentas. Our data also show that the unique species-specific difference in the biology of the rat and human placentas is reflected in the occurrence of completely different CSPG core protein types. Furthermore, the rat SSP-CSPG binds P. falciparum IRBCs in a CS chain-dependent manner. Since IRBCs have been reported to accumulate in the placentas of malaria parasite-infected rodents, our results have important implications for exploiting pregnant rats as a model for studying chondroitin 4-sulfate-based therapeutics for human placental malaria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16954212     DOI: 10.1074/jbc.M605841200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  2 in total

1.  Murine Model for Preclinical Studies of Var2CSA-Mediated Pathology Associated with Malaria in Pregnancy.

Authors:  Luciana V de Moraes; Sebastien Dechavanne; Patrícia M Sousa; André Barateiro; Sónia F Cunha; Sofia Nunes-Silva; Flávia A Lima; Oscar Murillo; Claudio R F Marinho; Stephane Gangnard; Anand Srivastava; Joanna A Braks; Chris J Janse; Benoit Gamain; Blandine Franke-Fayard; Carlos Penha-Gonçalves
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

2.  Chloroquine reduces arylsulphatase B activity and increases chondroitin-4-sulphate: implications for mechanisms of action and resistance.

Authors:  Sumit Bhattacharyya; Kemal Solakyildirim; Zhenqing Zhang; Robert J Linhardt; Joanne K Tobacman
Journal:  Malar J       Date:  2009-12-17       Impact factor: 2.979

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.